ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Topical Application of miR-200b-3p by Poloxamer 407-Based Hydrogel Accelerates Diabetic Wound Healing.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multifunctional Hydrogels for Diabetic Wound Healing: Design Strategies and Microenvironmental Remodeling Mechanisms.Gels (Basel, Switzerland) · 2026Review
- The Inflammaging-Redox-InflammamiR Axis in Metabolic Aging: From Diagnostic Clusters to Integrated Risk Phenotypes.Biomolecules · 2026Review
- Comparable Efficacy of Chitosan/miR-200b-3p and Lipofectamine/miR-200b-3p Delivered by Pluronic F127 Hydrogel to Facilitate Diabetic Wound Healing.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot ulcers (DFUs) are refractory to healing owing to excessive oxidative stress, increased proinflammatory cytokines, accumulation of senescent cells, and impaired angiogenesis. Local injections of miR-146a-5p and miR-200b-3p have pro-healing properties in diabetic wounds but are unrealistic in clinical practice. We investigated whether the topical application of miR-146a-5p and miR-200b-3p using a poloxamer 407-based hydrogel accelerated diabetic wound healing in db/db diabetic mice. In addition, we compared these two miRNAs to select a better microRNA for further application in patients with DFUs. Methods: The wound was created using an 8-mm punch biopsy. One hundred microliters of poloxamer P407 hydrogel formulations (gel, gel+miR-negative control, gel+miR-146a-5p, and gel+miR-200b-3p) were topically applied to each wound, and the hydrogel was changed every two days. Skin samples were sent for real-time PCR, H&E staining, and immunohistochemical staining. Results: On the 14th day, the gel+miR-200b-3p group demonstrated the best wound healing performance compared with the other three groups, as supported by the reduced wound size and enhanced granulation tissue thickness. Mechanistic insights showed that gel+miR-200b-3p caused significant upregulation of Conclusion: Topical application of miR-200b-3p by poloxamer 407 hydrogel showed better results in accelerating diabetic wound healing than miR-146a-5p. These data suggest that topical miR-200b-3p formulation is an effective treatment approach for DFUs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.